Restricted accessOtherFirst published online 2005-1
Heparin-Induced Thrombocytopenia;Hepatotoxicity with Newer Diabetes Agent;Acute Myocardial Infarction Associated with Albuterol;Olanzapine-Induced Hyperglycemic Hyperosmolar Nonketotic Coma;Paronychia and Skin Hyperpigmentation Due to Gefitinib;Selective Serotonin Reuptake Inhibitor-Induced Enuresis;Do Antidepressants Confer a Decreased Risk for Myocardial Infarction?;Recent Adverse Event Reviews;An Online Interview Discussing the Reduction of ADRs
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
LevineR.L., HurstingM.J., DrexlerA.Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med.2004; 44(5): 511–515.
2.
NanD., HernandezJ.L., Fernandez-AyalaM.Acute hepatotoxicity caused by repaglinide. Ann Int Med.2004; 141(10): 823.
3.
FisherA.A., DavisM.W., McGillD.A.Acute myocardial infarction associated with albuterol. Ann Pharmacother.2004; 38(12): 2045–2049.
4.
McCallM., BourgeoisJ.A.Olanzapine-induced hyperglycemic hyperosmolar nonketotic coma: a case report. J Clin Psychopharmacol.2004; 24(6): 670–673.
5.
ChangG.C., YangT.Y., ChenK.C.Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol.2004; 22(22): 4646–4648.
6.
MonjiA., YanagimotoK., YoshidaI.SSRI-induced enuresis: a case report. J Clin Psychopharmacol.2004; 24(5): 564–565.
7.
MonsterT.B., JohnsenS.P., OlsenM.L.Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med.2004; 117(10): 732–737.
8.
ElliottJ.P., IstwanN.B., RheaD.The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy. Am J Obstet and Gynecol.2004; 191(4): 1277–1282.
9.
Alsheikh-AliA.A., KuvinJ.T., KarasR.H.Risk of adverse events with fibrates. Am J Cardiol.2004; 94(7): 935–938.
10.
TokarskiC.Reducing adverse drug events by improving reliability: A newsmaker interview with Roger Resar, MD. Available at: http://www.medscape.com/viewarticle/493643_print. Accessed on November 17, 2004.
